Celularity Stock
Biotechnology Company
Sign up today and learn more about Celularity Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Celularity Stock
Celularity is a developer of therapies designed to treat autoimmune and degenerative diseases, immuno-oncology and functional regeneration. The company's therapies productize allogeneic cells and tissues derived from the postpartum placenta and have the ability to augment immunity and longevity by amplifying the body's ability to fight disease, heal and regenerate itself, enabling patients to begin treatment more quickly, resulting in a better medical outcome.
Investors
Celgene
Human Longevity
Section 32
Celularity, Freenome, Dialpad, Lime, Metromile, Primer, Vineti, Kobalt, BigHat Biosciences
Sorrento Therapeutics
United Therapeutics
Funding History
| August 2017 | $185M |
|---|---|
| August 2017 | $75.0M |
| May 2018 | $565M |
Management
Chief Executive Officer
Robert Hariri
Chief Financial Officer
David Beers
Press
news - Sep, 8 2020
Celularity Doses First Patient in Clinical Trial Evaluating CYNK-001 in COVID-19 Patientsmassdevice - Jun, 11 2020
Sanuwave announces intent to acquire Celularity’s UltraMistNew York Times - Apr, 2 2020
Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus PatientsCNBC - Mar, 31 2020
First cell treatment to fight the coronavirus awaits FDA approval for clinical trialWall Streets Journal - Mar, 13 2020
Celularity Joins Cast of Drugmakers Targeting New CoronavirusEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
